Fosun Pharma acquired Dongting Pharma to Jointly Develop CNS Drugs
On December 21, Fosun Pharma made an announcement to enter the field of CNS drugs by acquiring Hunan Dongting Pharmaceutical Co., Ltd. (hereinafter referred to as Dongting Pharma). It is reported that Fosun Pharma will purchase 77.777% of the equity interest of Dongting Pharma after the acquisition.
In light of the high R&D and manufacturing entering barriers of anti-psychotropic drugs, Fosun Pharma always pays more attention in the indication. Currently, the market of anti-schizophrenic drugs is expanding gradually at a stable growth rate. And the annual compound growth rate of domestic CNS drugs market is approximately 20%.
With the development of national economy and ever-intensifying social competition, various psychological stress factors increase dramatically and the mental health problem becomes increasingly prominent. According to the statistics of the Mental Health Center of China Center for Disease Control and Prevention, the number of patients with mental diseases of different degrees in China exceeded 100 million in 2011, including more than 16 million of them with serious mental diseases. However, only less than 20% of these patients can receive systematic and effective treatment currently.
Dongting Pharma is a leading enterprise in the field of anti –psychotic drugs in China with its major products - quetiapine fumarate and tranexamic acid. As one of the five principal antipsychotic drugs in the world, the global sales of quetiapine fumarate in 2011 exceeded US$ 5 billion and Dongting Pharma currently leads the market share of domestic quetiapine fumarate products with IMS data. Meanwhile, the company has established a reliable product quality control system through years of endeavors and development, and the traditional superior product tranexamic acid has passed multiple international bulk drug certifications such as FDA, COS, MHRA, and PMDA and has been exported to a number of countries around the world in a volume ranking first in the domestic export market and with a high reputation at the international market.
Chen Qiyu, the president of Fosun Pharma expresses that the field of domestic anti-psychotic drugs has long time been absolutely dominated by multi-national pharmaceutical companies; as a leading domestic enterprise in this field, Dongting Pharma has an attractive R&D pipeline based on the launched products. Fosun Pharma not only has many drugs for nervous system on the current research and development platform which can be directly docked with the manufacturing facility of Dongting Pharma, but also will help the latter to achieve a faster development in the field of anti-psychotic drugs by taking advantages of its capital, talent resources, management and R&D, so as to bring more choices of affordable drugs and better services to patients. Meanwhile, the cooperation will further enrich the pipeline of Fosun Pharma in the field of CNS Drugs, enhance the company’s competitiveness of Pharmaceutical manufacturing, and raise Fosun Parma’s position in the industry as well.
In light of the high R&D and manufacturing entering barriers of anti-psychotropic drugs, Fosun Pharma always pays more attention in the indication. Currently, the market of anti-schizophrenic drugs is expanding gradually at a stable growth rate. And the annual compound growth rate of domestic CNS drugs market is approximately 20%.
With the development of national economy and ever-intensifying social competition, various psychological stress factors increase dramatically and the mental health problem becomes increasingly prominent. According to the statistics of the Mental Health Center of China Center for Disease Control and Prevention, the number of patients with mental diseases of different degrees in China exceeded 100 million in 2011, including more than 16 million of them with serious mental diseases. However, only less than 20% of these patients can receive systematic and effective treatment currently.
Dongting Pharma is a leading enterprise in the field of anti –psychotic drugs in China with its major products - quetiapine fumarate and tranexamic acid. As one of the five principal antipsychotic drugs in the world, the global sales of quetiapine fumarate in 2011 exceeded US$ 5 billion and Dongting Pharma currently leads the market share of domestic quetiapine fumarate products with IMS data. Meanwhile, the company has established a reliable product quality control system through years of endeavors and development, and the traditional superior product tranexamic acid has passed multiple international bulk drug certifications such as FDA, COS, MHRA, and PMDA and has been exported to a number of countries around the world in a volume ranking first in the domestic export market and with a high reputation at the international market.
Chen Qiyu, the president of Fosun Pharma expresses that the field of domestic anti-psychotic drugs has long time been absolutely dominated by multi-national pharmaceutical companies; as a leading domestic enterprise in this field, Dongting Pharma has an attractive R&D pipeline based on the launched products. Fosun Pharma not only has many drugs for nervous system on the current research and development platform which can be directly docked with the manufacturing facility of Dongting Pharma, but also will help the latter to achieve a faster development in the field of anti-psychotic drugs by taking advantages of its capital, talent resources, management and R&D, so as to bring more choices of affordable drugs and better services to patients. Meanwhile, the cooperation will further enrich the pipeline of Fosun Pharma in the field of CNS Drugs, enhance the company’s competitiveness of Pharmaceutical manufacturing, and raise Fosun Parma’s position in the industry as well.